BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis

Oncology Letters

Volumn 4, Issue 1, 2012, Pages 141-145

  Hilton, J ^a   Weberpals, J ^b   Lorimer, I ^b   Amin, S ^c   Islam, S ^c   Pelletier, L ^c   Daneshmand, M ^b   Hanson, J ^b   Nabavi, M ^c   Parolin, D ^b   Mallick, R ^b   Verma, S ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

BRCA1; Breast cancer; Neoadjuvant therapy; Pathological complete response; PIK3CA mutations

Indexed keywords

BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DISEASE MARKER; DNA DAMAGE; DNA SEQUENCE; FEMALE; FISHER EXACT TEST; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOCALLY ADVANCED BREAST CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84861313995     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.697     Document Type: Article

References (21)

1. Gralow JR, Burstein HJ, Wood W, et al: Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26: 814-819, 2008.
2. Kleer CG, van Golen KL and Merajver SD: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2: 423-429, 2000.
3. Fisher B, Bryant J, Wolmark N, et al: The effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
4. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
5. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002.
6. Von Minckwitz G, Blohmer JU, Raab G, et al: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16: 56-63, 2005.
7. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
8. Smith LA, Cornelius VR, Plummer CJ, et al: Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10: 337-351, 2010.
9. Weberpals JI, Clark-Knowles KV and Vanderhyden BC: Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 26: 3259-3267, 2008.
10. Gennari A, Sormani M, Varesco L, et al: Prognostic significance of BRCA1, PARP1 and PARP2 in sporadic breast cancer. J Clin Oncol 27s: e22114, 2009.
11. Yoshikawa K, Honda K, Inamoto T, et al: Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5: 1249-1261, 1999.
12. Zhao L and Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496, 2008.
13. Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510, 2008.
14. Kalinsky K, Jacks LM, Heguy A, et al: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059, 2009.
15. Papaxoinis G, Pectasides D, Wirtz RM, et al: Prognostic significance of PI3K mRNA expression in patients with operable, high risk breast cancer. J Clin Oncol 27s: 577, 2009.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 45: 228-247, 2009.
17. Weberpals JI, Tu D, Squire JA, et al: Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 22: 2403-10, 2011.
18. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
19. Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929, 2005.
20. Karakas B, Bachman KE and Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94: 455-459, 2006.
21. Carser JE, Quinn JE, Michie CO, et al: BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 123: 492-498, 2011.